top of page

Amyotrophic Lateral Sclerosis (ALS)

Cannabis and Amyotrophic Lateral Sclerosis: Hypothetical and Practical Applications, and a Call for Clinical Trials 

Carter, Gregory, et al.

American Journal of Hospice & Palliative Medicine. 2010 Aug, 27(5): 347-356.

The endocannabinoid system in the inflammatory and neurodegenerative properties of multiple sclerosis and of amyotrophic lateral sclerosis

Rossi, Silvia, et al.

Experimental Neurology. 2010 July, 224(1): 92-102.

The endocannabinoid system in targeting inflammatory neurodegenerative diseases

Centonze, Diego, et al.

Trends in Pharmacological Sciences. 2007 Apr, 28(4): 180-187.

The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset

Shoemaker, Jennifer, et al.

Journal of Neurochemistry. 2007 Apr, 101(1): 97-98. 

AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis  

Kim, Kathline, et al.

European Journal of Pharmacology. 2006 Aug, 542(1-3): 100-105. 

Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival

Weydt, Patrick, et al.

Amyotrophic Lateral Sclerosis. 2005, 6(3): 182-184.

Survey of cannabis use in patients with amyotrophic lateral sclerosis.

Amtmann, Dagmar, et al.

American Journal of Hospice & Palliative Medicine. 2004 Mar, 21(2): 95-104.

Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid 

Raman, Chandrasekran, et al.

Amyotrophic Lateral Sclerosis. 2004, 5(1): 33-39.  

Neuroprotection by Delta-9 Tetrahydrocannabinol, the Main Active Compound in Marijuana, against Oubain-Induced In Vivo Excitotoxicity

van der Stelt, M, et al.

The Journal of Neuroscience. 2001 Sep 1, 21(17): 6475-6479.

ALS: About Us
bottom of page